SEP-227,162

SEP-227,162 is an antidepressant being developed by Sepracor which is currently in clinical trials. It acts as a serotonin-norepinephrine reuptake inhibitor. As of 1st July 2009, the compound has not shown sufficient efficacy, and its future development is unknown.